** Shares of drugmaker Amgen AMGN.O down 1.74% at $284 premarket
** Co said U.S. FDA has placed a clinical hold on an early-stage trial of an experimental weight-loss drug, AMG 513
** The hold is to protect trial participants from unreasonable risk and to ensure that studies are conducted properly - AMGN
** Co added, discussions with regulators are ongoing to determine a path to reopen the study, and they do not believe the issue leading to the hold is drug-related
** AMGN posted a higher quarterly profit and said late-stage studies of another key obesity drug candidate, MariTide, will start before mid-year
** Obesity will continue to be a key theme for Amgen shares as we enter 2025 - Brokerage BMO Capital Markets
** Up to last close, stock down ~10% in last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。